Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renato Mantegazza

Showing results (1-10 of 242) with videos related to

Pageof 25
Sort By:
The New England Journal of Medicine|December 10, 2003
Antimyelin antibodies in multiple sclerosisRenato Mantegazza
Expert Review of Clinical Pharmacology|October 23, 2019
Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndromeRenato Mantegazza
Expert Opinion on Pharmacotherapy|September 15, 2022
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?Fiammetta Vanoli, Renato Mantegazza
Current Opinion in Rheumatology|August 7, 2019
Diagnosis and treatment of myasthenia gravisRenato Mantegazza, Paola Cavalcante
Expert Opinion on Biological Therapy|February 28, 2023
Ravulizumab for the treatment of myasthenia gravisFiammetta Vanoli, Renato Mantegazza
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 15, 2022
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic ManagementFiammetta Vanoli, Renato Mantegazza
Clinical Drug Investigation|August 6, 2011
Treatment of myasthenia gravis: focus on pyridostigmineLorenzo Maggi, Renato Mantegazza
Patient Related Outcome Measures|October 25, 2023
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia GravisCarlo Antozzi, Renato Mantegazza
Expert Opinion on Pharmacotherapy|April 14, 2023
Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravisFiammetta Vanoli, Renato Mantegazza
Frontiers in Neurology|September 28, 2020
From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for ResearchRenato Mantegazza, Carlo Antozzi
Pageof 25

Showing results (1-10 of 242) with videos related to

Sort By:
Pageof 25
The New England Journal of Medicine|December 10, 2003
Antimyelin antibodies in multiple sclerosisRenato Mantegazza
Expert Review of Clinical Pharmacology|October 23, 2019
Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndromeRenato Mantegazza
Expert Opinion on Pharmacotherapy|September 15, 2022
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?Fiammetta Vanoli, Renato Mantegazza
Current Opinion in Rheumatology|August 7, 2019
Diagnosis and treatment of myasthenia gravisRenato Mantegazza, Paola Cavalcante
Expert Opinion on Biological Therapy|February 28, 2023
Ravulizumab for the treatment of myasthenia gravisFiammetta Vanoli, Renato Mantegazza
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 15, 2022
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic ManagementFiammetta Vanoli, Renato Mantegazza
Clinical Drug Investigation|August 6, 2011
Treatment of myasthenia gravis: focus on pyridostigmineLorenzo Maggi, Renato Mantegazza
Patient Related Outcome Measures|October 25, 2023
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia GravisCarlo Antozzi, Renato Mantegazza
Expert Opinion on Pharmacotherapy|April 14, 2023
Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravisFiammetta Vanoli, Renato Mantegazza
Frontiers in Neurology|September 28, 2020
From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for ResearchRenato Mantegazza, Carlo Antozzi
Pageof 25